Greenway Medical Technologies (Carrolton, Georgia) said it participated in the recent National Health IT Week's Capitol Hill Technology Showcase, held in Washington. The showcase marked one of the healthcare IT industry's first real-time demonstrations of ambulatory software providers exchanging healthcare data between disparate EHR systems.

Greenway, NextGen Healthcare Information Systems, IBM and Initiate Systems all took part in the demonstration. During National Health IT Week, public and private entities collaborated to advance health IT adoption with "one voice, one vision."

"Greenway is excited with the success and collaboration achieved by two of the HIT industry's leading EHR providers," said Justin Barnes, VP of marketing and government affairs for the company. "The showcase effectively demonstrated the reality of data sharing from one ambulatory product to another and the call to action is clear, it is time we bring interoperability from a concept into a practical working exchange that will improve the quality of healthcare across the board and afford EHR adoption incentives such as the Stark relaxation to increase EHR availability."

Greenway Medical Technologies provides ambulatory healthcare business solutions and services.

LCA-Vision opens Nashville LasikPlus store

LCA-Vision (Cincinnati), a provider of laser vision correction services under the LasikPlus brand, reported the opening of its 77th LasikPlus vision center in Nashville, Tennessee. This opening marks the fifth LasikPlus vision center the company has opened this year, and is the first LasikPlus first vision center located in the state of Tennessee.

Merge regains Nasdaq compliance

Merge Healthcare (Milwaukee) it has received notification from the Nasdaq stock market that the company had regained compliance with Nasdaq marketplace rule 4450(a)(5) and that Nasdaq now considers the matter closed.

The company was notified on April 2 that it was not in compliance with the minimum bid price rule because shares of its common stock had closed at a bid price of less than $1 for 30 consecutive business days. At that time, in accordance with marketplace rule 4450(e)(2), the company was provided with 180 calendar days, or until Sept. 29, to regain compliance. Since then, the company's common stock maintained a closing bid price at $1 or greater for at least 10 consecutive business days.

Merge Healthcare makes medical imaging software.

BSD Medical delivers response to FDA

BSD Medical (Salt Lake City) said that a formal response has been delivered to the FDA pertaining to the BSD-2000 hyperthermia system submission that is currently in review by the agency.

The response followed an in-person meeting with the FDA management and reviewers in which the company's response strategy was discussed before the company made its formal response.

BSD Medical makes systems used to deliver hyperthermia therapy for the treatment of cancer.

Life Recovery Systems moves HQ

Life Recovery Systems HD (Waldwick, New Jersey), a maker of products for the emergency medical care market, has moved to a larger space in the Hopper Technology Center, 150 Hopper Avenue, Waldwick. The company had been headquartered in Kinnelon, New Jersey.

Life Recovery makes the ThermoSuit System, a noninvasive hypothermia device, which reduces core body temperature in a patient to between 33 degrees centigrade and 37 degrees centigrade in a matter of minutes. The system continuously pumps a thin film of ice water around the patient's body until the temperature reaches a preset level. This technology cools patients at a rate of one degree centigrade for every seven minutes of treatment. The duration of cooling treatment required to achieve target temperature is typically 20 to 30 minutes.

Theragenics reports favorable Medicare news

Theragenics (Buford, Georgia) reported favorable developments in Medicare reimbursement policies related to brachytherapy. On July 15, the Medicare Improvements for Patients and Providers Act of 2008 was enacted into law.

The new law extends Medicare's longstanding reimbursement safeguards (originally enacted in 2003) for brachytherapy seeds administered in the hospital outpatient setting through Dec. 31, 2009, ensuring that the Medicare program does not implement potentially restrictive caps on reimbursement during that period. The longstanding policy actually expired after June 30, 2008, but the new Act is retroactive to July 1.

"Theragenics has worked diligently for many years to ensure prostate cancer patients have access to all treatment options," said Christine Jacobs, chairman/CEO of Theragenics, the manufacturer and marketer of the TheraSeed and I-Seed brachytherapy devices.